We are live on ! Find out more
SCM

Soleus Capital Management Portfolio holdings

AUM $2.9B
1-Year Est. Return 169.69%
This Fund
S&P 500
This Quarter Est. Return
+26.15%
1 Year Est. Return
+169.69%
3 Year Est. Return
+507.65%
5 Year Est. Return
+746.04%
10 Year Est. Return
–
AUM
$2.9B
AUM Growth
+$433M
Cap. Flow
-$46.5M
Cap. Flow %
-1.6%
Top 10 Hldgs %
48.91%
Holding
114
New
21
Increased
25
Reduced
41
Closed
17

Top Buys

Rank Stock Value
1
PODD icon
Insulet
PODD
+$81.1M
2
INSP icon
Inspire Medical Systems
INSP
+$64.3M
3
RIGL icon
Rigel Pharmaceuticals
RIGL
+$56.6M
4
CELC icon
Celcuity
CELC
+$48.5M
5
PBLS
Parabilis Medicines Inc
PBLS
+$40.5M

Top Sells

Rank Stock Value
1
TWST icon
Twist Bioscience
TWST
+$73M
2
KRYS icon
Krystal Biotech
KRYS
+$63.9M
3
PRAX icon
Praxis Precision Medicines
PRAX
+$48.4M
4
TGTX icon
TG Therapeutics
TGTX
+$45.1M
5
VCEL icon
Vericel Corp
VCEL
+$39.2M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BDSX icon
51
Biodesix
BDSX
$276M
$13.2M 0.46%
585,958
+169,359
+41% +$2.51M
SYRE icon
52
Spyre Therapeutics
SYRE
$7.85B
$13.1M 0.45%
+147,000
New +$10.7M
TWST icon
53
Twist Bioscience
TWST
$8.21B
$10.8M 0.37%
104,629
-1,122,000
-91% -$73M
VIR icon
54
Vir Biotechnology
VIR
$1.93B
$10.2M 0.35%
1,000,000
-1,002,000
-50% -$9.53M
ALNY icon
55
Alnylam Pharmaceuticals
ALNY
$35.6B
$9.95M 0.34%
33,050
-98,600
-75% -$29.7M
IMVT icon
56
Immunovant
IMVT
$8.11B
$9.71M 0.33%
252,000
+22,000
+10% +$670K
INSM icon
57
Insmed
INSM
$27.6B
$9.62M 0.33%
90,250
+80,000
+780% +$9.69M
SEPN
58
Septerna Inc
SEPN
$1.72B
$9.21M 0.32%
275,000
– –
SOPH icon
59
SOPHiA GENETICS
SOPH
$689M
$9.03M 0.31%
1,565,000
-285,000
-15% -$1.45M
NKTR icon
60
Nektar Therapeutics
NKTR
$2.53B
$8.96M 0.31%
+128,362
New +$9.39M
MIRM icon
61
Mirum Pharmaceuticals
MIRM
$6.15B
$8.78M 0.3%
75,000
-325,306
-81% -$32.7M
AORT icon
62
Artivion
AORT
$1.25B
$8.72M 0.3%
+388,000
New +$10.9M
TNDM icon
63
Tandem Diabetes Care
TNDM
$1.38B
$8.68M 0.3%
575,000
-208,000
-27% -$3.63M
ELVN icon
64
Enliven Therapeutics
ELVN
$4.35B
$8.41M 0.29%
165,677
-65,192
-28% -$2.77M
SION
65
Sionna Therapeutics
SION
$325M
$7.82M 0.27%
177,687
-115,813
-39% -$4.63M
BLTE
66
Belite Bio
BLTE
$7.8B
$7.78M 0.27%
+50,524
New +$7.74M
CERS icon
67
Cerus
CERS
$522M
$7.3M 0.25%
2,500,000
-8,253,700
-77% -$20M
SLN
68
Silence Therapeutics
SLN
$907M
$6.92M 0.24%
+630,000
New +$4.43M
IMUX icon
69
Immunic
IMUX
$179M
$6.92M 0.24%
450,000
– –
IVVD icon
70
Invivyd
IVVD
$243M
$6.73M 0.23%
7,708,727
– –
MRK icon
71
Merck
MRK
$371B
$6.42M 0.22%
50,000
-153,000
-75% -$17.9M
RLMD icon
72
Relmada Therapeutics
RLMD
$473M
$5.83M 0.2%
842,106
– –
GPCR icon
73
Structure Therapeutics
GPCR
$3.38B
$5.74M 0.2%
107,000
+27,000
+34% +$1.19M
EOLS icon
74
Evolus
EOLS
$614M
$5.71M 0.2%
822,428
-1,422,932
-63% -$8.4M
ANL
75
Adlai Nortye Group ADS
ANL
$967M
$4.66M 0.16%
+405,523
New +$4.93M
1 2
3
4 5

Similar funds

GA
General Atlantic New York $2.91B AUM 24.21% 1-Year Est. Return
LSA
Leonteq Securities AG Zurich, Switzerland $2.91B AUM 56.5% 1-Year Est. Return
7WCP
71 West Capital Partners Boston, Massachusetts $2.89B AUM
ACM
Aquatic Capital Management Chicago, Illinois $2.91B AUM 27.09% 1-Year Est. Return
HWA
Heritage Wealth Advisors Richmond, Virginia $2.91B AUM 24.25% 1-Year Est. Return
JC
JB Capital Wethersfield, Connecticut $2.89B AUM 29.25% 1-Year Est. Return
WPW
Waldron Private Wealth Bridgeville, Pennsylvania $2.89B AUM 23.18% 1-Year Est. Return
BWL
Bogart Wealth LLC Mclean, Virginia $2.92B AUM 23.85% 1-Year Est. Return

Soleus Capital Management's Q2 2026 Portfolio in Review

As of Q2 2026, Soleus Capital Management held 114 positions worth $2.9B, up 18% from $2.47B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Soleus Capital Management's Q2 2026 filing shows 21 new, 25 increased, 41 reduced and 17 closed positions. Its largest new stake was Parabilis Medicines Inc: 1,465,070 shares worth $40.1M. The largest sale was Twist Bioscience, an estimated $73M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Soleus Capital Management's largest Q2 2026 buy was Parabilis Medicines Inc: 1,465,070 shares worth $40.1M.
  • Soleus Capital Management added most to Insulet in Q2 2026, an estimated $81.1M increase.
  • Soleus Capital Management's biggest Q2 2026 reduction was Twist Bioscience, cutting an estimated $73M.
  • Soleus Capital Management fully exited Vaxcyte in Q2 2026, selling an estimated $22.4M.
  • Soleus Capital Management's ten largest holdings make up 49% of its $2.9B portfolio in Q2 2026.
  • Soleus Capital Management opened 21 new positions and closed 17 in Q2 2026.
  • Soleus Capital Management's portfolio value rose 18% quarter-over-quarter to $2.9B.

Based on Soleus Capital Management's 13F filing for Q2 2026, filed 11 Aug 2026.